1
|
Abstract
Humanized anti-c-erbB-2 antibodies (Herceptin®) in a weekly schedule are a new therapeutic option for the treatment of c-erbB-2-positive, advanced breast cancer (ABC). Addition of Herceptin® to first-line chemotherapy for c-erbB-2 overexpressing ABC increased anticancer activity in a randomized phase III trial. However, except from standard UICC response criteria, there are hitherto no recommendations as to how to monitor Herceptin® therapy. In a therapy optimizing study with weekly dose-intensified paclitaxel monotherapy (schedule: 90 mg/m2 weekly x 6, q9w), we correlated the clinical course of stage IV breast cancer in UICC criteria with the course of the shed c-erbB-2 protein fragment and the CA 27.29 serum level. Serum samples were taken weekly from 35 patients to measure the serum c-erbB-2 and CA 27.29 protein levels over time. Up to now, 10 patients (28.5%) are c-erbB-2 positive (>15 U/mL), with a median baseline protein expression of 65 U/mL. While the overall response rate in the study is 36%, the response rate among c-erbB-2-positive patients is 62%, indicating a high sensitivity of c-erbB-2 positive patients to dose-intense paclitaxel treatment. In all responders the c-erbB-2 serum level decreased below the detection limit either before the clinical diagnosis of response or by the end of the next cycle. However, the normalization of the c-erbB-2 serum level was not specific for responders as patients with stable or progressive disease presented normalized levels or a >50% decrease of the baseline level, too. The courses of the c-erbB-2 protein levels correlated closely with the courses of CA 27.29. The decrease in the serum c-erbB-2 oncoprotein level might indicate a regression of c-erbB-2 positive tumor load. This may even happen in progressive disease according to UICC criteria when the c-erbB-2-negative tumor fraction progresses while the c-erbB-2-positive fraction is controlled. Another explanation would be that the mechanisms of c-erbB-2 shedding change under chemotherapy, with less of the c-erbB-2 protein fragment being released to the serum, which would make the c-erbB-2 positive tumor cells a better target for anti-c-erbB-2 antibody treatment.
Collapse
Affiliation(s)
- D Lüftner
- Medizinische Klinik, Humboldt-Universität Berlin, Germany.
| | | | | |
Collapse
|
2
|
Luftner D, Henschke P, Kafka A, Anagnostopoulos I, Wiechen K, Geppert R, Stein H, Wernecke KD, Kreienberg R, Possinger K. Discordant Results Obtained for Different Methods of HER-2/Neu Testing in Breast Cancer – A Question of Standardization, Automation and Timing. Int J Biol Markers 2018; 19:1-13. [PMID: 15077921 DOI: 10.1177/172460080401900101] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Background HER-2/neu positivity is required for the selection of stage IV breast cancer patients for trastuzumab therapy. We compared the results of the recommended immunohistochemistry (IHC) evaluation with the automated ACIS™ IHC system and with fluorescence in situ hybridization (FISH). These HER-2/neu tissue results were correlated with the serum HER-2/neu (sHER-2/neu) levels at the time of metastatic spread. Patients and Methods A total of 61 IHC slides from 30 patients were stained using the HercepTest™. HER-2/neu gene amplification was determined using the Ventana™ FISH assay. sHER-2/neu levels were measured with the Oncogene Science” ELISA kit. The concordance of HER-2/neu results was determined using the concordance index Kappa (κ). Results The best concordance between any IHC and FISH was found for the automated ACIS system (88.5%, κ=0.68, category “good”). The comparison between the manual interpretations and the automated IHC was categorized as “very good” (95.1%, κ=0.85). The median sHER-2/neu level of FISH positive patients was significantly higher (67 ng/mL) than that of FISH negative patients (17 ng/mL, p=0.018). The increase in HER-2/neu positivity comparing tissue to stage IV serum was statistically significant (p=0.001). Conclusions The concordance between conventional IHC and computerized analysis was very good. The number of patients with stage IV breast cancer with an elevated sHER-2/neu level was much higher than HER-2/neu positivity in tissue. This discrepancy is only partially explained by the influence of tumor load. Patients with an elevated sHER-2/neu level and no tissue overexpression should be considered for retesting of tissue or a new biopsy.
Collapse
Affiliation(s)
- D Luftner
- Medizinische Klinik und Poliklinik II, Schwerpunkt Onkologie und Hämatologie, Universitätsklinikum Charité, Humboldt-Universität, Berlin, Germany.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Lüftner D, Cheli C, Mickelson K, Sampson E, Possinger K. ADVIA Centaur® Her-2/Neu Shows Value in Monitoring Patients with Metastatic Breast Cancer. Int J Biol Markers 2018; 19:175-82. [PMID: 15503818 DOI: 10.1177/172460080401900301] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Introduction The proteolytic breakdown product corresponding to the extracellular domain (ECD) of the HER-2/neu oncoprotein p185 is found in the circulation of healthy individuals and patients having cancers of epithelial origin. For the current evaluation we sought to determine the analytical performance as well as the clinical utility of the newly developed ADVIA Centaur® HER-2/neu assay (Bayer HealthCare LLC, Diagnostics Division, Tarrytown, NY, USA) in monitoring patients with metastatic breast cancer during the course of disease and treatment and to compare the obtained results with those of CA 15–3. Methods The analytical performance (including precision, normal range, interfering substances, minimum detectable concentration, dilution recovery, spiking recovery and high-dose hook effect) were determined. HER-2/neu and CA 15–3 values were measured in retrospective samples obtained from 59 patients with metastatic breast cancer undergoing treatment over a 6–12 month period. Serial changes in serum HER-2/neu and CA 15–3 were correlated with changes in clinical status on a visit-to-visit basis. For each pair of serial measurements, changes of equal to or greater than, or less than 15% for HER-2/neu and 21% for CA 15–3 were considered to indicate progression or lack of progression, respectively. Results The ADVIA Centaur HER-2/neu assay demonstrated within-run imprecision and total imprecision ranging from 3.0–5.6% and from 3.2–5.7%, respectively. The upper limit of normal was 15.2 ng/mL (90% CI: 14.2–17.0 ng/mL). No significant interference (<5%) was seen with bilirubins, hemoglobin, triglycerides and cholesterol or therapeutic drugs commonly present in the sera of breast cancer patients. The minimum detectable concentration (analytical sensitivity) was found to be 0.5 ng/mL. The patient population in the clinical study included breast cancer patients who responded to therapy (stable, partial or complete response) or had disease progression. HER-2/neu levels showed a concordance of 78.1% (82/105 restaging time points) with the clinical course of disease, whereas CA 15–3 levels showed a concordance of 76.2% (80/105 restaging time points). The concordance with clinical status increased to 85.7% (90/105 restaging time points) when both results were used in combination as a series test. Conclusions The ADVIA Centaur HER-2/neu assay provides excellent analytical performance for serial testing of serum HER-2/neu levels. The clinical data demonstrate the usefulness of serum HER-2/neu in monitoring metastatic breast cancer patients during treatment. Furthermore, the results indicate that serum HER-2/neu and CA 15–3 may be useful in identifying disease progression or therapeutic response in different subgroups of women with metastatic breast cancer.
Collapse
Affiliation(s)
- D Lüftner
- Medizinische Klinik und Poliklinik II, Schwerpunkt Onkologie und Hämatologie, Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, Berlin--Germany.
| | | | | | | | | |
Collapse
|
4
|
Maass N, Greiner W, Possinger K, Tesch H, Förster F, Schneeweiss A, Düwel P, Ostermann H. ACT-FASTER: Eine epidemiologische, prospektive Kohortenstude bei postmenopausalen Frauen mit fortgeschrittenem, HR-positivem Brustkrebs mit Fulvestrant und Exemestan unter Alltagsbedingungen. Geburtshilfe Frauenheilkd 2014. [DOI: 10.1055/s-0034-1388446] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
5
|
Meyer AH, Stroux A, Lerch K, Eucker J, Eitle J, Hohloch K, Andrzejak M, Possinger K, Dörken B, Pezzutto A, Scholz CW. Transformation and additional malignancies are leading risk factors for an adverse course of disease in marginal zone lymphoma. Ann Oncol 2014; 25:210-5. [PMID: 24356632 DOI: 10.1093/annonc/mdt507] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND Marginal zone lymphoma (MZL) is a non-Hodgkin lymphoma that occurs as extra nodal, nodal, or splenic. While MZL is generally considered an indolent disease, a substantial percentage of patients follow an unfavorable course. The objective of this retrospective analysis was to identify predictors for a reduced overall survival (OS), or conversely an increased OS. PATIENTS AND METHODS One hundred and ninety-seven MZL patients were analyzed. Apart from assessing previously published risk factors, concomitant morbidity at diagnosis, transformation into aggressive lymphoma, and occurrence of additional malignancies were evaluated. RESULTS Next to the known risk factors, i.e. above 60 years of age and elevated serum lactate dehydrogenase (LDH), we demonstrate that transformation into aggressive lymphoma, as well as additional malignancies, are important independent risk factors for a shortened OS in a multivariate analysis, irrespective of the MZL localization. Impressively, in the group of patients lacking LDH elevation, transformation, and/or additional malignancies, only 1 of 63 patients died during follow-up compared with 37 of 87 patients in the high-risk group (HR = 22.8; 95% confidence interval 3.1-167.0; P = 0.002). CONCLUSIONS Our analysis proposes novel risk factors and warrants for a continuous follow-up to detect the occurrence of transformation and additional malignancies early on.
Collapse
Affiliation(s)
- A H Meyer
- Department of Hematology, Oncology and Tumor Immunology
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Regierer AC, Wolters R, Ufen MP, Weigel A, Novopashenny I, Köhne CH, Samonigg H, Eucker J, Possinger K, Wischnewsky MB. An internally and externally validated prognostic score for metastatic breast cancer: analysis of 2269 patients. Ann Oncol 2014; 25:633-638. [PMID: 24368402 PMCID: PMC4433507 DOI: 10.1093/annonc/mdt539] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2013] [Revised: 10/28/2013] [Accepted: 11/04/2013] [Indexed: 01/15/2023] Open
Abstract
BACKGROUND The prognosis of metastatic breast cancer (MBC) is extremely heterogeneous. Although patients with MBC will uniformly die to their disease, survival may range from a few months to several years. This underscores the importance of defining prognostic factors to develop risk-adopted treatment strategies. Our aim has been to use simple measures to judge a patient's prognosis when metastatic disease is diagnosed. PATIENTS AND METHODS We retrospectively analyzed 2269 patients from four clinical cancer registries. The prognostic score was calculated from the regression coefficients found in the Cox regression analysis. Based on the score, patients were classified into high-, intermediate-, and low-risk groups. Bootstrapping and time-dependent receiver operating characteristic curves were used for internal validation. Two independent datasets were used for external validation. RESULTS Metastatic-free interval, localization of metastases, and hormone receptor status were identified as significant prognostic factors in the multivariate analysis. The three prognostic groups showed highly significant differences regarding overall survival from the time of metastasis [intermediate compared with low risk: hazard ratio (HR) 1.76, 95% confidence interval (CI) 1.36-2.27, P < 0.001; high compared with low risk: HR 3.54, 95% CI 2.81-4.45, P < 0.001). The median overall survival in these three groups were 61, 38, and 22 months, respectively. The external validation showed congruent results. CONCLUSIONS We developed a prognostic score, based on routine parameters easily accessible in daily clinical care. Although major progress has been made, the optimal therapeutic management of the individual patient is still unknown. Besides elaborative molecular classification of tumors, simple clinical measures such as our model may be helpful to further individualize optimal breast cancer care.
Collapse
Affiliation(s)
- A C Regierer
- Department of Oncology and Hematology, Charité - Universitätsmedizin Berlin, Berlin.
| | - R Wolters
- Department of Mathematics and Computer Science, University Bremen, Bremen
| | - M-P Ufen
- Department of Oncology and Hematology, Klinikum Oldenburg, Oldenburg, Germany
| | - A Weigel
- Department of Oncology and Hematology, Charité - Universitätsmedizin Berlin, Berlin
| | - I Novopashenny
- Department of Mathematics and Computer Science, University Bremen, Bremen
| | - C H Köhne
- Department of Oncology and Hematology, Klinikum Oldenburg, Oldenburg, Germany
| | - H Samonigg
- Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
| | - J Eucker
- Department of Oncology and Hematology, Charité - Universitätsmedizin Berlin, Berlin
| | - K Possinger
- Department of Oncology and Hematology, Charité - Universitätsmedizin Berlin, Berlin
| | - M B Wischnewsky
- Department of Mathematics and Computer Science, University Bremen, Bremen
| |
Collapse
|
7
|
Regierer AC, Wolters R, Ufen MP, Weigel A, Novopashenny I, Köhne CH, Samonigg H, Eucker J, Possinger K, Wischnewsky MB. An internally and externally validated prognostic score for metastatic breast cancer: analysis of 2269 patients. Ann Oncol 2013. [PMID: 24368402 DOI: 10.1093/annonc.mdt539] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
BACKGROUND The prognosis of metastatic breast cancer (MBC) is extremely heterogeneous. Although patients with MBC will uniformly die to their disease, survival may range from a few months to several years. This underscores the importance of defining prognostic factors to develop risk-adopted treatment strategies. Our aim has been to use simple measures to judge a patient's prognosis when metastatic disease is diagnosed. PATIENTS AND METHODS We retrospectively analyzed 2269 patients from four clinical cancer registries. The prognostic score was calculated from the regression coefficients found in the Cox regression analysis. Based on the score, patients were classified into high-, intermediate-, and low-risk groups. Bootstrapping and time-dependent receiver operating characteristic curves were used for internal validation. Two independent datasets were used for external validation. RESULTS Metastatic-free interval, localization of metastases, and hormone receptor status were identified as significant prognostic factors in the multivariate analysis. The three prognostic groups showed highly significant differences regarding overall survival from the time of metastasis [intermediate compared with low risk: hazard ratio (HR) 1.76, 95% confidence interval (CI) 1.36-2.27, P < 0.001; high compared with low risk: HR 3.54, 95% CI 2.81-4.45, P < 0.001). The median overall survival in these three groups were 61, 38, and 22 months, respectively. The external validation showed congruent results. CONCLUSIONS We developed a prognostic score, based on routine parameters easily accessible in daily clinical care. Although major progress has been made, the optimal therapeutic management of the individual patient is still unknown. Besides elaborative molecular classification of tumors, simple clinical measures such as our model may be helpful to further individualize optimal breast cancer care.
Collapse
Affiliation(s)
- A C Regierer
- Department of Oncology and Hematology, Charité - Universitätsmedizin Berlin, Berlin.
| | - R Wolters
- Department of Mathematics and Computer Science, University Bremen, Bremen
| | - M-P Ufen
- Department of Oncology and Hematology, Klinikum Oldenburg, Oldenburg, Germany
| | - A Weigel
- Department of Oncology and Hematology, Charité - Universitätsmedizin Berlin, Berlin
| | - I Novopashenny
- Department of Mathematics and Computer Science, University Bremen, Bremen
| | - C H Köhne
- Department of Oncology and Hematology, Klinikum Oldenburg, Oldenburg, Germany
| | - H Samonigg
- Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
| | - J Eucker
- Department of Oncology and Hematology, Charité - Universitätsmedizin Berlin, Berlin
| | - K Possinger
- Department of Oncology and Hematology, Charité - Universitätsmedizin Berlin, Berlin
| | - M B Wischnewsky
- Department of Mathematics and Computer Science, University Bremen, Bremen
| |
Collapse
|
8
|
Ufen MP, Köhne CH, Wischneswky M, Wolters R, Novopashenny I, Fischer J, Constantinidou M, Possinger K, Regierer AC. Metastatic breast cancer: are we treating the same patients as in the past? Ann Oncol 2013; 25:95-100. [PMID: 24276026 DOI: 10.1093/annonc/mdt429] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Abstract
BACKGROUND Early detection and improved (neo)-adjuvant treatment has extended survival of breast cancer over the last decades. It remains controversial whether a survival benefit is achieved once metastases have occurred. This study investigates survival trends in metastatic breast cancer (MBC) looking at the distribution of prognostic factors and the time period of the diagnosis of the primary and metastatic disease. PATIENTS AND METHODS In this retrospective study, 1635 patients, diagnosed with MBC and treated at three German cancer centers, were included. For the survival analysis, patients were grouped into three time periods [1980-1994 (a), 1995-1999 (b) and 2000-2009 (c)], which were chosen according to the availability of new antineoplastic drugs for the treatment of MBC. Additionally, patients were divided into three risk groups using the simultaneously published prognostic score. RESULTS The analysis of overall survival according to the date of primary diagnosis demonstrated a significant decline compared with the reference (a): (a versus b) hazard ratio (HR) = 1.37; P < 0.001; (a versus c) HR = 2.45; P < 0.001. Considering the time of first occurrence of metastasis, survival remains unchanged over the three periods (a versus b): HR = 0.94 P = 0.436; (a versus c): HR = 0.95; P = 0.435. However, a significant shift towards more unfavorable risk factors was seen. CONCLUSIONS Although survival in MBC remains unchanged over time, patients developing metastatic disease have a more aggressive disease that is presumably compensated by more effective treatment. This alteration of tumor biology in MBC may be explained by a negative selection of patients with adverse risk profiles due to the advantages of the adjuvant therapy.
Collapse
Affiliation(s)
- M-P Ufen
- University Clinic for Oncology and Haematology at the Klinikum Oldenburg, Oldenburg
| | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Jehn CF, Flath B, Strux A, Krebs M, Possinger K, Pezzutto A, Lüftner D. Influence of age, performance status, cancer activity, and IL-6 on anxiety and depression in patients with metastatic breast cancer. Breast Cancer Res Treat 2012; 136:789-94. [PMID: 23124416 DOI: 10.1007/s10549-012-2311-2] [Citation(s) in RCA: 46] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2012] [Accepted: 10/19/2012] [Indexed: 12/01/2022]
Abstract
Depression and anxiety are the core disorders causing emotional distress in patients (pts) with metastatic breast cancer. The aim of our study was to screen metastatic breast cancer outpatients for anxiety and depression, and to investigate the influence of age, Karnofsky Performance Status (KPS), cancer activity, and inflammation as represented by IL-6 levels on these two mood disorders. Pts treated with chemotherapy for metastatic breast cancer (n = 70) were assessed using the Hospital Anxiety and Depression Scale (HADS) for symptoms (scores 0-21) and caseness (score ≥11) of clinical depression and anxiety. Blood samples for IL-6 concentrations were collected at 10:00 a.m. A total of 22 (31.4 %) pts were diagnosed with caseness of clinical depression and 23 (32.9 %) pts with clinical anxiety, while 12 pts were diagnosed positive for both mood disorders. Depression and anxiety were positively but moderately correlated (Spearman's r (2) = 0.24, p < 0.001). IL-6 was significantly correlated with symptoms of depression (r (2) = 0.42, p < 0.001) and to a lesser extent to symptoms of anxiety (r (2) = 0.16, p = 0.001). In addition, IL-6 was positively associated with tumor progression (p < 0.001). Multiple linear regression analysis showed that tumor progression (standardized b = 0.226, p = 0.047), symptoms of anxiety (b = 0.292, p = 0.016), and IL-6 (b = 0.314, p = 0.007) were independently associated with clinical depression, whereas anxiety was linked to tumor progression (b = 0.238, p = 0.030), symptoms of depression (b = 0.407, p < 0.001) and age (b = -0.381, p < 0.001), but not to IL-6 (b = 0.168, p = 0.134). Even though a positive correlation between depression and anxiety exists, clinical parameters like age, cancer activity, KPS, and IL-6 do influence depression and anxiety differently. Unlike clinical depression, anxiety is not associated with increased IL-6 levels, however, shows a reciprocal correlation with age.
Collapse
Affiliation(s)
- C F Jehn
- Medizinische Klinik m. S. Hämatologie, Onkologie und Tumorimmunologie, Charité Campus Virchow, Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany.
| | | | | | | | | | | | | |
Collapse
|
10
|
Abstract
BACKGROUND Clinical trials under-represent patients (pts) >65 years. Non-interventional studies (NISs) help to evaluate therapies in daily practice. This NIS evaluates efficacy and safety of cetuximab in combination with chemotherapy in metastatic colorectal cancer (mCRC) pts aged >65 years vs ≤ 65 years. METHODS A total of 657 pts were recruited into the NIS and analysed applying descriptive statistics and χ(2) or Fisher's exact test. RESULTS A total of 309 and 305 pts aged ≤ 65 and >65 years, respectively, were documented; 80% showing a reduced ECOG status of 1-2 and 95% having received at least one palliative treatment. Cetuximab was combined with irinotecan according to approval status. Grade III/IV toxicities occurred in 20% of pts without any difference between age groups although the older pts had significantly more pre-existing comorbidities (P=0.001). A total of 64.2% of the pts developed skin rash, which was strongly related to response (P<0.0002) without any difference between age groups (P=0.34). The objective response rates were 37.9% for ages 18-65 years vs 35.4% for >65 years. Progression-free survival (PFS) did not differ between pts 18-65 years old (6.5 months) in comparison with pts >65 years (7.0 months). In a multivariate analysis only ECOG status had a negative impact on PFS (HR: 0,675; 95% Cl, 0.53-0.87; P=0.0019). CONCLUSION This NIS reports one of the largest mCRC collectives >65 years and reduced performance status. Cetuximab has a similar efficacy and safety profile for pts aged ≤ 65 and >65 years.
Collapse
Affiliation(s)
- C F Jehn
- Medizinische Klinik und Poliklinik m. S. Onkologie & Hämatologie; Charité Campus Mitte, Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany
| | | | | | | | | |
Collapse
|
11
|
Wolters R, Regierer A, Schwentner L, Geyer V, Possinger K, Kreienberg R, Wischnewsky M, Wöckel A. A comparison of international breast cancer guidelines – Do the national guidelines differ in treatment recommendations? Eur J Cancer 2012; 48:1-11. [DOI: 10.1016/j.ejca.2011.06.020] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2011] [Revised: 06/07/2011] [Accepted: 06/07/2011] [Indexed: 11/27/2022]
|
12
|
Jehn C, Böning L, Kroning H, Possinger K, Lueftner D. Analysis of skin toxicity in elderly patients (older than age 65) with metastatic colorectal cancer (mCRC) treated with cetuximab: Results of a German Noninterventional Study (NIS). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e14129] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
13
|
Eucker J, Schwarzlose-Schwarck S, Martus P, Regierer AC, Schulz CO, Liu H, Scholz CW, Schefe JH, Possinger K. Phase I trial with carboplatin and RAD001 in metastatic breast cancer. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e11554] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
14
|
Eucker J, Possinger K. [Individualized treatment of breast cancer]. Dtsch Med Wochenschr 2011; 136:486-91. [PMID: 21365526 DOI: 10.1055/s-0031-1274532] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
Breast cancer is the most frequent tumor in women. Clinical research over the last few years has resulted in an increasing differentiation of treatment strategies in the adjuvant setting as well as in metastatic breast cancer. In recent years, the medical treatment of breast cancer was complemented by agents with new mechanisms of action that depend on biological properties of the tumor. As these agents target tumor specific characteristics they are called targeted agents or targeted therapy. Most frequently, different receptors, key proteins of intracellular pathways, thyrosinkinases, or cytokines serve as tumor targets. Even in endocrine treatment relevant changes of practical guidelines emerged. The most important targeted therapies are reviewed with special regard to metastatic breast cancer.
Collapse
Affiliation(s)
- J Eucker
- Medizinische Klinik mit Schwerpunkt Onkologie und Hämatologie, Charité - Universitätsmedizin Berlin, Campus Charité Mitte, Charitéplatz 1, 10117 Berlin.
| | | |
Collapse
|
15
|
Seidel J, Kunc K, Possinger K, Lueftner DI. Abstract P2-06-21: RNAi Silencing of CUB-Domaining Containing Protein 1 (CDCP1) in Breast Cancer Cell Lines Results in Decreased Migration and Invasion Capacities In Vitro.. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p2-06-21] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The orphan surface receptor CDCP1 is over-expressed in various cancers and signals via Src family kinases (SFKs). It has been shown to be involved in anchorage independency of distinct tumors [Uekita et al. 2007; Moasser 2009]. Since CDCP1 is also speculated to be involved in tumor cell migration and invasion, the following study investigated the in vitro migration and invasion of breast cancer cell lines. In order to prove if lapatinib treatment might benefit CDCP1-positive but HER2/neu-negative breast cancer patients, we investigated the level of apoptosis after lapatinib application to different cell lines.
Material and Methods: Four breast cancer cell lines were selected according to their CDCP1/HER-2/neu receptor expression (MDA-MB-231high/high; T47Dhigh/low; SKBR3low/high; MCF7neg./high). CDCP1 knock-down was achieved via nucleofection of Stealth™ RNAi (Invitrogen) against CDCP1. In vitro migration and invasion were analyzed for 48hs using trans-well assays (Merck). Migrated cells were labeled with Calcein AM and relative fluorescence units (RFU) were measured at 485/520nm. To investigate the effect of lapatinib, cells were cultured for 48hs in the presence of lapatinib (0,75 µM) as attached cells or as suspension culture on ultra-low adhesion plates, respectively. The enrichment of free nucleosomes was measured and compared between CDCP1-RNAi transfected and parental cells.
Results: When transfected with CDCP1-RNAi, migration of SKBR-3 cells was not affected (96.2% migrating cells compared to control). However, CDCP1-RNAi-transfected MDA-MB-231 cells showed a strong reduction in migration (70.2% (± 21.5%)) compared to mock-transfected cells and the observed effect was even more impressive in T47D cells (58.3± 16.1% migration compared to control; P=0,011)). Invasion of CDCP1- silenced MDA-MB-231 was reduced to 71.4% (± 5.9%) of the mock-transfected control cells. Again, T47D cells also were severely impaired by CDCP1-knock-down (0.32 ± 0.02% of invasive cells compared to control; P<0.01). Lapatinib had no effect on either MDA-MB-231 cells or T47D cells at any culture conditions. However, the level of apoptotic SKBR3 cells significantly increased when cultured in suspension (1.5x) as well as adherent cells (1.8x) in the presence of lapatinib independent of CDCP1-knock down.
Conclusions: The migratory activity of breast cancer cell lines did not strictly correlate with the degree in CDCP1 expression. However, CDCP1- knock down yielded in a clearly reduced migration and invasion of MDA-MB-231 cells and was even more impressive in T47D cell line. However, no effect was observed in SKBR3 cells. Thus, CDCP1 might represent one of a panel of surface receptors that participate in cell movement. However, Lapatinib was shown to have no effect on the viability of CDCP1pos./Her2/neuneg./low cells. Nonetheless, our study reveals that CDCP1 might have a strong impact on migration and invasive capacities of breast cancer cell lines and thus represents a potential target in more individualized breast cancer therapies.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P2-06-21.
Collapse
Affiliation(s)
- J Seidel
- Charite University Medicine, Berlin, Germany
| | - K Kunc
- Charite University Medicine, Berlin, Germany
| | - K Possinger
- Charite University Medicine, Berlin, Germany
| | | |
Collapse
|
16
|
Possinger K. Tribute to Professor H. Stobbe. Oncol Res Treat 2010. [DOI: 10.1159/000218607] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
17
|
Jehn C, Stenzel K, Böning L, Kröning H, Possinger K, Lueftner D. Results of a german noninterventional study (NIS) of cetuximab-based therapy in pretreated-patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.3632] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
18
|
Schmid P, Kiewe P, Possinger K, Korfel A, Lindemann S, Giurescu M, Reif S, Wiesinger H, Thiel E, Kühnhardt D. Phase I study of the novel, fully synthetic epothilone sagopilone (ZK-EPO) in patients with solid tumors. Ann Oncol 2010; 21:633-639. [DOI: 10.1093/annonc/mdp491] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
19
|
Seidel J, Bruemann C, Kunc K, Possinger K, Lueftner D. Evaluation of CUB-Domain-Containing Protein (CDCP1)-Expression as Predictive Marker of Adhesion-Independant Cell Survival in Breast Cancer Cell Lines. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-09-6167] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: A crucial step in the metastatic cascade is to overcome anoikis, a type of programmed cell death after loss of cell-cell contact. CDCP1 has recently been indentified to be an essential prerequisite for anoikis resistance in lung adenocarcinoma cell lines [Uekita et al. 2007]. CDCP1 is overexpressed in distinct tumor tissues and suspected to signal via Src family kinases (SFK). Since CDCP1 overexpression has been detected in a variety of primary breast cancers and cell lines [Bühring et al. 2004], this study aimed at investigating the correlation between CDCP1 expression and anoikis-resistance in breast cancer cell lines and the involvement of SFKs.Material and Methods: Various breast cancer cell lines were tested for their CDCP1 status by FACS analysis and immunoblotting. CDCP1-negative breast cancer cell line MCF7 and primary normal breast cells were compared to the CDCP1-high cell lines MDA-MB-231 (∼90% positive cells (p.c.)), T47D (∼65% p.c.), SKBR3 (∼52% p.c.) and HBL100 (∼60% p.c.) when cultured in ultra low-adhesion culture plates. Apoptosis rate was evaluated measuring the nucleosome enrichment factor (EF). SFK-involvement was tested via proliferation analysis after treatment with SKF-inhibitor PP2 and its inactive derivate PP3. Since various types of breast cancer were influenced by the presence or absence of steroids, MDA-MB-231 cells and HBL100 cells were stimulated with ß17-Estradiol and CDCP1 expression was measured using relative quantification in qRT-PCR.Results: When grown in solution on ultra-low adhesion plates, CDCP1-negative primary normal breast cells underwent apoptosis (EF:5,29). CDCP1-high expressing MDA-MB-231 cells (EF:1,75) were less apoptotic than T47D (EF:3,68:) and SKBR3 cells (EF:4,35). However, CDCP1-negative MCF7 breast cancer cells were relatively resistant towards loss of anchorage (EF:2,03). When grown in suspension, proliferation rate of MDA-MB-231 is 6-fold lower than in normal tissue plates, both cultured with or without SFK-inhibitor PP2. Proliferation rate of CDCP1-negative MCF7 cells grown in solution in presence and absence of PP2 is even 24-fold reduced. MDA-MB-231 cells show a significant 50% reduction in RNA-levels of CDCP1 when cultured 48h in presence of ß17-ER (10-8M). However, in HBL100 cells, no change of RNA-level of CDCP1 was detectable.Conclusions: Anoikis resistance seems to directly correlate with the expression level of CDCP1, when cells are cultured in suspension. However, CDCP1-negative cell line MCF7 also shows relative resistance towards loss of anchorage. Thus, anoikis resistance may not be a monocausal phenomenon. Nonetheless, high level of CDCP1-expression also promotes cell proliferation in absence of anchorage to an extracellular matrix. RNAi-mediated knock-down will elucidate if CDCP1 is also involved in cell migration or invasion. Our studies show, that CDCP1-expression level has strong impact on the capacity of breast cancer cell lines to grow and survive anchorage independent - an essential prerequisite for metastatic potential.
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 6167.
Collapse
Affiliation(s)
- J. Seidel
- 1Charité Universitätsmedizin Berlin, Germany
| | - C. Bruemann
- 1Charité Universitätsmedizin Berlin, Germany
| | - K. Kunc
- 1Charité Universitätsmedizin Berlin, Germany
| | | | - D. Lueftner
- 1Charité Universitätsmedizin Berlin, Germany
| |
Collapse
|
20
|
Lüftner D, Schelenz C, Possinger K. Verschreibungsverhalten von Aromataseinhibitoren in der adjuvanten endokrinen Therapie des Mammakarzinoms – eine aktuelle Bestandsaufnahme unter Meinungsbildnern in Deutschland. Geburtshilfe Frauenheilkd 2009. [DOI: 10.1055/s-0029-1186259] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
21
|
Beslija S, Bonneterre J, Burstein H, Cocquyt V, Gnant M, Heinemann V, Jassem J, Köstler W, Krainer M, Menard S, Petit T, Petruzelka L, Possinger K, Schmid P, Stadtmauer E, Stockler M, Van Belle S, Vogel C, Wilcken N, Wiltschke C, Zielinski C, Zwierzina H. Third consensus on medical treatment of metastatic breast cancer. Ann Oncol 2009; 20:1771-85. [DOI: 10.1093/annonc/mdp261] [Citation(s) in RCA: 146] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023] Open
|
22
|
Schwartzberg LS, Sankar SL, Apt D, Goldstein E, Vetticaden SJ, Chitour K, Gilfoyle D, Kim S, Keilholz U, Possinger K. An open-label, dose-escalating study of Maxy-G34, a novel potent, long-acting Pegylated G-CSF, compared with pegfilgrastim (PF) for the treatment of chemotherapy induced neutropenia (CIN). J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e14500] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e14500 Background: rhG-CSF reduces the incidence and duration of CIN in patients (pts) receiving myelosuppressive chemotherapy. Maxy-G34 is a recombinant, modified human G-CSF, containing three 5 kD PEG groups. These modifications alter both renal and receptor mediated clearance, leading to a longer half-life and the potential for enhanced activity. Phase I studies demonstrated safety of Maxy-G34 in normal volunteers with a dose dependent rapidly reversible increase in the absolute neutrophil count (ANC). The effect of Maxy-G34 on CIN was evaluated in an open-label, active-comparator controlled, dose-ranging study. Methods: The primary efficacy endpoint was duration of severe, Grade 4 neutropenia (G4N) in treatment cycle 1. Adults with high-risk Stage I-IIIa breast cancer eligible for TAC chemotherapy received Maxy-G34 at 10, 30, 45, 60 or 100 μg/kg or the active control PF 6 mg, given sub- cutaneously 24-hours after each dose of TAC for 6 cycles. Blood samples were collected daily and analyzed at a central laboratory throughout each of the 21-day chemotherapy cycles to determine ANC and evaluate PK profile of Maxy-G34. Results: All dose groups of Maxy-G34 enrolled 6 pts each, except the 100 μg/kg group (3 pts), and the PF group (8 pts). The mean durations of G4N in cycle 1 were 2.2 days for 10 μg/kg, 1.8 days for 30 μg/kg, 0.8 days for 45 μg/kg, 2.2 days for 60 μg/kg, and 1.7 days for 100 μg/kg Maxy-G34 groups vs. 2.0 days for PF. The rate of FN was 2.6% across all Maxy-G34 doses vs. 4.2% for PF. CD34+ cell counts increased across Maxy-G34 groups following recovery from nadir with maximum concentration in treatment cycle 1 ranging from 25.8 to 133.3 cells/mL versus 49.6 cells/mL for PF. The average half-life and Cmax obtained after Maxy-G34 were approximately 2-fold higher than PF. Adverse events were consistent with those reported for G-CSF and TAC with no serious unexpected adverse events. Grade 3/4 AEs for Maxy-G34 was 9.5% vs. 8.5% for PF. No neutralizing antibodies related to Maxy-G34 were observed. Conclusion: Once-per-cycle Maxy-G34 appears to be effective in reducing CIN with no new safety signals. Further Phase II studies are planned. [Table: see text]
Collapse
Affiliation(s)
- L. S. Schwartzberg
- The West Clinic, Memphis, TN; Maxygen, Inc, Redwood City, CA; Charité Hospital, Berlin, Germany
| | - S. L. Sankar
- The West Clinic, Memphis, TN; Maxygen, Inc, Redwood City, CA; Charité Hospital, Berlin, Germany
| | - D. Apt
- The West Clinic, Memphis, TN; Maxygen, Inc, Redwood City, CA; Charité Hospital, Berlin, Germany
| | - E. Goldstein
- The West Clinic, Memphis, TN; Maxygen, Inc, Redwood City, CA; Charité Hospital, Berlin, Germany
| | - S. J. Vetticaden
- The West Clinic, Memphis, TN; Maxygen, Inc, Redwood City, CA; Charité Hospital, Berlin, Germany
| | - K. Chitour
- The West Clinic, Memphis, TN; Maxygen, Inc, Redwood City, CA; Charité Hospital, Berlin, Germany
| | - D. Gilfoyle
- The West Clinic, Memphis, TN; Maxygen, Inc, Redwood City, CA; Charité Hospital, Berlin, Germany
| | - S. Kim
- The West Clinic, Memphis, TN; Maxygen, Inc, Redwood City, CA; Charité Hospital, Berlin, Germany
| | - U. Keilholz
- The West Clinic, Memphis, TN; Maxygen, Inc, Redwood City, CA; Charité Hospital, Berlin, Germany
| | - K. Possinger
- The West Clinic, Memphis, TN; Maxygen, Inc, Redwood City, CA; Charité Hospital, Berlin, Germany
| |
Collapse
|
23
|
Liu H, Schulz CO, Regierer AC, Dieing A, Possinger K, Eucker J. TKI258, a novel, multitargeted tyrosine kinase inhibitor for the treatment of breast cancer. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e14625] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e14625 TKI258 (4-amino-5-fluor-3-[5-(4-metylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one, formerly known as CHIR258) is an ATP-competitive inhibitor with activities against class III or IV receptor kinases, which include FGFR, VEGFR, PDGFR, FLT3, and KIT. It has been demonstrated to possess strong anti-tumor and anti-angiogenetic activities in different tumor models, and, therefore, this compound is currently being clinically assessed for the treatment of diverse malignancies. In this study, we chose the breast cancer cell line MDA-MB-231, a cell line with high invasive capacities, as an in vitro model to analyze the effect and functional mechanism of TKI258 on the breast cancer invasiveness. Treatment of MDA-MB-231 cells with TKI258 resulted in reduced invasive capacities in a dose-dependent manner. In association with this effect, we observed that TKI258 down-regulated the phosphorylation of ERK1/2 and STAT3 and inhibited the VEGF production in the cell supernatants. Most interestingly, we found TKI258 had influence on the inflammatory chemokines CCL5 and CCL2 level if MDA-MB-231 cells were co-cultured with breast cancer stroma cells. We found that CCL5/CCL2 mRNA level in MDA-MB-231 cells, in stroma cells, or in co-culture of MDA-MB-231/breast cancer stroma was strongly inhibited by TKI258 as detected with real-time PCR. Parallel to this result, the dramatically elevated CCL2/CCL5 level in the media supernatants from co-cultured MDA-MB-231/stroma cells was reduced by TKI258 effectively. Furthermore, we demonstrated that the invasion-promoting effect of the tumor stroma cells was antagonized by TKI258 significantly. CCL5 stimulated invasion of MDA-MB-231 cells could be partially abrogated by TKI58 and/or by CCL5-neutralizing antibody. Therefore, it is most likely that the inhibitory effect of TKI258 on invasion of MDA-MB-231 cells in the presence of stroma cells is achieved, at least in part, by antagonizing the invasion-promoting effect of CCL5. Overall, our data show that TKI258 inhibited invasive capacities of aggressive breast cancer cell line MDA-MB-231, either in the absence or presence of tumor stroma cells in vitro. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- H. Liu
- Charité Campus Mitte, Berlin, Germany
| | | | | | - A. Dieing
- Charité Campus Mitte, Berlin, Germany
| | | | - J. Eucker
- Charité Campus Mitte, Berlin, Germany
| |
Collapse
|
24
|
|
25
|
Possinger K. Einführung. Oncol Res Treat 2009. [DOI: 10.1159/000218502] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
26
|
Heidemann E, Steinke B, Hartlapp J, Schumacher K, Possinger K, Kunz S, Neeser E, Ingersleben G, Hossfeld D, Caffier H, Souchon R, Waldmann R, Blümner E, Clark J. Prognostic Subgroups: The Key Factor for Treatment Outcome in Metastatic Breast Cancer. Oncol Res Treat 2009. [DOI: 10.1159/000218287] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
27
|
linger C, Herrmann R, Berdel W, Kleeberg U, Gatzemeier U, Illiger H, Wander H, Westerhausen M, Becher R, Bremer K, Rieche K, Essers U, Queißer W, Heidemann E, Fiebig H, Possinger K, Jourdain-Madl B, Heim M, Edler L. Topically Applied Miltefosine (Hexadecylphosphocholine) in Patients with Skin-Metastasized Breast Cancer. A Phase II Study. Oncol Res Treat 2009. [DOI: 10.1159/000218252] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
28
|
Lux MP, Benedict A, Buchholz S, Woeckel A, Harbeck N, Kreienberg R, Kaufmann M, Beckmann MW, Jonat W, Hadji P, Distler W, Raab G, Tesch H, Weyers G, Schneeweiss A, Possinger K. Cost-effectiveness of anastrozole versus tamoxifen as adjuvant therapy in early breast cancer (EBC) – a German health economic analysis. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-6109] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Abstract #6109
Background: The non-steroidal aromatase inhibitor (AI) anastrozole is superior to tamoxifen in terms of efficacy and safety in the adjuvant treatment of postmenopausal patients with hormone receptor-positive (HR+) early breast cancer (EBC). The aim of the current study was to evaluate the cost-effectiveness of anastrozole versus tamoxifen from the German health care perspective.
 Methods: A probabilistic Markov model was developed using data from the published literature and expert opinion to project trial outcomes to 25 years based on a cohort of 1000 postmenopausal women with HR+ EBC. Resource use data and costs were obtained from standard sources and expert opinion. Utility scores for the different heath states were obtained from a patient-based utility study using the standard gamble technique. Results were expressed as incremental cost-effectiveness ratios (ICERs) per quality adjusted life-years (QALYs) gained. Costs and benefits were discounted at 5% annually.
 Results: Total costs over the 25 year period for anastrozole and tamoxifen were €12,422 and €6,757, respectively. The cost per life year (LY) for anastrozole compared to tamoxifen was €24,822/LY gained. The ICER of anastrozole compared to tamoxifen was €21,050/QALY gained (95% CI €9,841 - €62,344). The result remained robust to all parameters tested in the sensitivity analysis. Cost-effectiveness probability curves indicated a >90% probability that the cost per QALY gained with anastrozole would be <€42,000.
 Conclusions: In this model, five years of adjuvant anastrozole is a cost-effective treatment alternative to tamoxifen in postmenopausal women with HR+ EBC from the German health care perspective.
Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 6109.
Collapse
Affiliation(s)
- MP Lux
- 1 University Breast Center Franconia, University of Erlangen, Erlangen, Germany
- 14 Department of Oncology, Charité Berlin, Berlin, Germany
| | - A Benedict
- 2 United BioSource Cooperation, Budapest, Hungary
- 14 Department of Oncology, Charité Berlin, Berlin, Germany
| | - S Buchholz
- 3 Department of Gynecology, University of Regensburg, Regensburg, Germany
- 14 Department of Oncology, Charité Berlin, Berlin, Germany
| | - A Woeckel
- 4 Department of Gynecology, University of Ulm, Ulm, Germany
- 14 Department of Oncology, Charité Berlin, Berlin, Germany
| | - N Harbeck
- 5 Women's Hospital, Technical University, Munich, Germany
- 14 Department of Oncology, Charité Berlin, Berlin, Germany
| | - R Kreienberg
- 4 Department of Gynecology, University of Ulm, Ulm, Germany
- 14 Department of Oncology, Charité Berlin, Berlin, Germany
| | - M Kaufmann
- 6 Centre for Gynecology and Obstetrics, University of Frankfurt, Frankfurt, Germany
- 14 Department of Oncology, Charité Berlin, Berlin, Germany
| | - MW Beckmann
- 1 University Breast Center Franconia, University of Erlangen, Erlangen, Germany
- 14 Department of Oncology, Charité Berlin, Berlin, Germany
| | - W Jonat
- 7 Department of Gynecology and Obstetrics, Christian-Albrechts-University of Kiel, Kiel, Germany
- 14 Department of Oncology, Charité Berlin, Berlin, Germany
| | - P Hadji
- 8 Department of Gynecology and Gyn-Oncology, Philipps-University of Marburg, Marburg, Germany
- 14 Department of Oncology, Charité Berlin, Berlin, Germany
| | - W Distler
- 9 Department of Gynecology and Obstetrics, University of Dresden, Dresden, Germany
- 14 Department of Oncology, Charité Berlin, Berlin, Germany
| | - G Raab
- 10 Practice for Gynecology, Practice for Gynecology, Munich, Germany
- 14 Department of Oncology, Charité Berlin, Berlin, Germany
| | - H Tesch
- 11 Oncological Practice, Frankfurt, Germany
- 14 Department of Oncology, Charité Berlin, Berlin, Germany
| | - G Weyers
- 12 Practice for Cardiology, Bergisch Gladbach, Germany
- 14 Department of Oncology, Charité Berlin, Berlin, Germany
| | - A Schneeweiss
- 13 Day Clinic for Gynecological Oncology, University of Heidelberg, Heidelberg, Germany
- 14 Department of Oncology, Charité Berlin, Berlin, Germany
| | - K Possinger
- 14 Department of Oncology, Charité Berlin, Berlin, Germany
| |
Collapse
|
29
|
Liu H, Possinger K, Eucker J. Combination of carboplatin and the mTor inhibitor RAD001 is a new therapeutic approach for p53-mutated breast cancer. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-405] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Abstract #405
Platinum agents are very effective and commonly used chemotherapeutics for the treatment of many solid tumors. However, acquired and intrinsic resistance remains a major obstacle for platinum-based therapy. Recent evidence indicates that mTOR inhibition is a promising strategy to sensitize some p53-wild type solid tumors to conventional chemotherapies. Since p53-mutation is a common phenomenon in breast cancer, we investigated in this study the possibilities of the combined application of carboplatin and the mTOR inhibitor RAD001 in these human breast cancer cells in vitro.
 Combination of carboplatin and RAD001 resulted in synergistic inhibitions of cell proliferation both in p53-wild type (MCF-7, ZR-75), and in p53-mutated (SKBR-3, BT-474, BT-20), as well as drug resistant (tamoxifen-resistant MCF-7, adriamycin-resistant MCF-7) breast cancer cell lines as analyzed with Calcusyn software. Higher doses of the two drugs resulted in synergistically apoptosis after 24- or 48-hours treatment independent of p53-status of breast cancer cells. Investigation of several cell survival signaling pathways revealed an additively decreased phosphorylation of Erk, STAT3 and Akt after co-treatment suggesting that interference of cell survival signaling may be one of the mechanisms responsible for growth inhibition mediated by this combination.
 With low doses of the two drugs, we observed impaired cell cycle progression, additively reduced cyclins and CDKs, and enhanced p27 level by flow cytometry analysis and western blot. No rapid apoptosis and caspases-involved cell death were observed. Immunohistological analysis after prolonged treatment with low doses of the two drugs demonstrated that carboplatin alone resulted in the formation of endopolyploid cells in p53-mutated breast cancer cells. RAD001 alone had not such an effect, but strengthened this effect of carboplatin. In addition, decreased level of cyclin B1, the main driver of mitosis, was detected by the co-treatment of the two drugs. These data collectively suggest that the combination use of low doses of carboplatin and RAD001 may present a strategy to overcome the resistance of breast cancer to chemotherapy. It is a promising combination that warrants clinical evaluation.
Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 405.
Collapse
Affiliation(s)
- H Liu
- 1 Department of Oncology and Hematology, Charité - University Hospital Berlin, Berlin, Germany
| | - K Possinger
- 1 Department of Oncology and Hematology, Charité - University Hospital Berlin, Berlin, Germany
| | - J Eucker
- 1 Department of Oncology and Hematology, Charité - University Hospital Berlin, Berlin, Germany
| |
Collapse
|
30
|
Jehn CF, Boulikas T, Kourvetaris A, Kofla G, Possinger K, Lüftner D. First safety and response results of a randomized phase III study with liposomal platin in the treatment of advanced squamous cell carcinoma of the head and neck (SCCHN). Anticancer Res 2008; 28:3961-3964. [PMID: 19192656] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
BACKGROUND Cisplatin is one of the most active chemotherapeutic agents used in the treatment of advanced squamous cell carcinoma of the head and neck (SCCHN). However, its clinical efficacy is limited by its renal and hematotoxicity profile. In a randomized, multicenter phase III trial, we replaced conventional cisplatin by a liposomal formulation of cisplatin (lipoplatin) and compared the safety and efficacy profiles of patients in the two treatment arms. PATIENTS AND METHODS Main inclusion criteria were: histologically confirmed SCCHN, age between 18-75 years with sufficient renal function. Main endpoints for this interims analysis were hemato- and nephrotoxicity. First response data were collected. RESULTS Forty-six patients were evaluable for outcome and toxicity. Grade III and IV hematotoxicity were more frequent in the cisplatin arm (31.7% vs. 12%), with grade IV leucopenia occurring in 22.2%. However, 16% of the patients in that treatment arm experienced grade III anemia compared to only 9.5% treated with the cisplatin regimen. A total 4% of the patients in the lipoplatin arm developed grade IV neuropathy, whereas in the cisplatin arm, 19% developed grade III neuropathy and none developed grade IV. The renal toxicity profile of both drugs also showed marked differences. In the cisplatin arm, 23.8% of patients suffered grade III toxicity. In contrast, no grade III or IV renal toxicity occurred in patients treated with lipoplatin. The efficacy results showed 38.8% objective partial remission in the cisplatin arm vs. 19% in the lipoplatin arm. However 64% of the patients achieved stable disease while being treated with lipoplatin/5-fluorouracil (5-FU), vs. 50% in the cisplatin/5-FU arm. CONCLUSION Liposomal cisplatin seems to reduce both the renal and hematological toxicity to a clinically relevant extent as compared to conventional cisplatin. The clinical benefit rate is similar for both regimens.
Collapse
Affiliation(s)
- C F Jehn
- Medizinische Klinik und Poliklinik mit Schwerpunkt Onkologie und Hämatologie Charité, Campus Mitte, Universitätsmedizin Berlin, Humboldt-Universität zu Berlin 10117 Berlin, Germany
| | | | | | | | | | | |
Collapse
|
31
|
|
32
|
Lux MP, Harbeck N, Hartmann M, Raab G, Schneeweiss A, Possinger K. Fulvestrant, eine kostennutzwerte Option in der palliativen Situation. – Ergebnisse des German Faslodex® health economic sequencing model. Geburtshilfe Frauenheilkd 2008. [DOI: 10.1055/s-0028-1088699] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
33
|
Jehn C, Kuehnhardt D, Schulz C, Krebs M, Flath B, Possinger K, Bode L, Eucker J. Association of Borna disease virus infection with depression in cancer patients. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.20514] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
34
|
Zander AR, Schmoor C, Kröger N, Krüger W, Möbus V, Frickhofen N, Metzner B, Berdel WE, Koenigsmann M, Thiel E, Wandt H, Possinger K, Kreienberg R, Schumacher M, Jonat W. Randomized trial of high-dose adjuvant chemotherapy with autologous hematopoietic stem-cell support versus standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: overall survival after 6 years of follow-up. Ann Oncol 2008; 19:1082-9. [PMID: 18304964 DOI: 10.1093/annonc/mdn023] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Investigation of high-dose chemotherapy (HD-CT) compared with standard-dose chemotherapy (SD-CT) as adjuvant treatment in patients with primary breast cancer and >/=10 axillary lymph nodes. From November 1993 to September 2000, 307 patients were randomized to receive after four cycles of epirubicin (90 mg/m(2)), cyclophosphamide (600 mg/m(2)) i.v. (every 21 days) and either HD-CT of cyclophosphamide (1500 mg/m(2)), thiotepa (150 mg/m(2)) and mitoxantrone (10 mg/m(2)) i.v. for four consecutive days followed by stem cell transplantation or a SD-CT of three cycles CMF (cyclophosphamide 500 mg/m(2), methotrexate 40 mg/m(2), 5-fluorouracil 600 mg/m(2), i.v. on day 1 and 8, respectively, every 28 days). After a median follow-up of 6.1 years, 166 events with respect to event-free survival (EFS) (SD-CT: 91, HD-CT: 75) have been observed. The hazard ratio of HD-CT versus SD-CT is estimated as 0.80 [95% confidence interval (0.59, 1.08)], P = 0.15. The trend to a superiority of HD-CT as compared with SD-CT with respect to EFS seems to be more pronounced in premenopausal patients as compared with postmenopausal patients and in patients with tumor grade 3 as compared with patients with tumor grade 1/2. With a follow-up of 6 years, there was a trend in favor of HD-CT with respect to EFS not being significant. A proper meta-analysis needs to be undertaken for an evaluation of subgroups of patients who might benefit from HD-CT.
Collapse
Affiliation(s)
- A R Zander
- Center of Oncology, Clinic for Stem Cell Transplantation, University Hospital Hamburg-Eppendorf, Hamburg, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Schmid P, Kühnhardt D, Kiewe P, Lehenbauer-Dehm S, Schippinger W, Greil R, Lange W, Preiss J, Niederle N, Brossart P, Freier W, Kümmel S, Van de Velde H, Regierer A, Possinger K. A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines. Ann Oncol 2008; 19:871-6. [PMID: 18209010 DOI: 10.1093/annonc/mdm569] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND Proteasome inhibitors are a novel class of compounds entering clinical trials as a method to increase tumour sensitivity to standard chemotherapy. This phase I/II trial was carried out to evaluate the combination of capecitabine and the proteasome inhibitor bortezomib in anthracycline and/or taxane-pretreated patients with metastatic breast cancer. PATIENTS AND METHODS A total of 35 patients were treated with bortezomib (1.0-1.3 mg/m(2) on days 1, 4, 8 and 11) and capecitabine (1500-2500 mg/m(2) on days 1-14) in 3-week intervals for up to eight cycles. RESULTS The maximum tolerated doses (MTDs) were bortezomib 1.3 mg/m(2) and capecitabine 2500 mg/m(2). The treatment was generally well tolerated and associated with toxic effects that were consistent with the known side-effects of the individual agents. The intent-to-treat overall response rate was 15% and an additional 27% of patients had stable disease (SD). In the 20 patients treated at the MTD, the response rate was 15% and 40% had SD. Median time to progression and overall survival were 3.5 months [95% confidence interval (CI) 1.9-4.4] and 7.5 months (95% CI 5.6-14.6), respectively. Median duration of response was 4.4 months. CONCLUSION The combination of bortezomib and capecitabine is well tolerated and has moderate antitumour activity in heavily pretreated patients.
Collapse
Affiliation(s)
- P Schmid
- Medical Oncology, Imperial College London, Charing Cross Hospital, London, UK.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Abstract
Due to its low incidence there is only few information on optimal systemic therapy of male breast cancer. There are no prospective randomized trials, neither for early breast cancer nor for advanced stages. Retrospective analyses mostly comprise long-term-data from a small number of patients. In terms of epidemiology, cellular receptors or genetics there exist some significant differences between male and female breast cancer. Therefore, the possibility to extrapolate treatment recommendation for male patients from female breast cancer-trials is limited. Despite a high rate of receptor positivity, hormonal therapy seems to be less efficient in men, possibly due to different biological factors. The current standard in endocrine therapy is tamoxifen. It is not known whether tamoxifen therapy is as effective as orchiectomy, but tamoxifen is favoured because of its low side effects. The use of aromatase inhibitors needs to be considered carefully, since aromatization is blocked, but 5-alpha-reductase increases estrogen-like androstanediole. There might be a benefit from additional therapy with GnRH-analoga respectively 5-alpha-reductase inhibitors, but data is not available yet. Combination of GnRH-analoga and antiandrogens does induce tumor remission, but comparison to other endocrine therapies is still lacking. Currently, the efficiency of fulvestrant, an estrogen receptor destructor, is being examined. Cytostatic therapy seems to be as effective as in female breast cancer patients. Nevertheless, convincing prospective trials for the management of early and advanced male breast cancer need to be performed.
Collapse
Affiliation(s)
- J Eucker
- Med Universitätsklinik und Poliklinik mit Schwerpunkt Onkologie und Hämatologie, Universitätsmedizin Berlin, Charite Campus Mitte, Berlin, Germany.
| | | | | |
Collapse
|
37
|
Albert U, Altland H, Duda V, Engel J, Geraedts M, Heywang-Köbrunner S, Hölzel D, Kalbheim E, Kaufmann M, Kreienberg R, Kreipe H, Lebeau A, Loibl S, Nass-Griegoleit I, Nestle-Krämling C, Possinger K, Schlake W, Schmutzler R, Schreer I, Schulte H, Schulz K, Schulz-Wendtland R, Wallwiener D, Bender H. Onkologie. Aktuelle Gesundheitsziele zur Sekundärprävention von Brustkrebs in Deutschland. Geburtshilfe Frauenheilkd 2007. [DOI: 10.1055/s-2007-965775] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
38
|
Lüftner D, Henschke P, Possinger K. Clinical value of bisphosphonates in cancer therapy. Anticancer Res 2007; 27:1759-68. [PMID: 17649770] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/16/2023]
Abstract
The therapeutic opportunities for an improved management of malignant bone disease are currently extensively studied. The conventional management of symptomatic bone lesions in patients with advanced cancer involves various combinations of local and systemic standard anticancer therapies and the symptomatic treatment of skeletal complications. In recent years, bisphosphonates have demonstrated high efficacy to avoid skeletal complications from metastatic bone lesions and to prevent cancer treatment-induced bone loss. Especially in the treatment of patients with bone metastases, secondary to breast cancer, a widespread use of bisphosphonates has been established. With the development of highly potent new-generation bisphosphonates, such as zoledronate, the therapeutic opportunities for bisphosphonates are going to expand. Several current studies have investigated the benefit of zoledronate therapy for bone metastases from a variety of tumor types, including prostate cancer, lung and renal cell cancer and multiple myeloma. Furthermore, bisphosphonates have been shown to significantly reduce antineoplastic therapy-induced bone loss. According to recently published data, it is suggested that bisphosphonates not only play a role in the inhibition of osteoclast-mediated bone resorption, but also have antitumor effects inhibiting tumor cell proliferation, adhesion and invasion, as well as angiogenesis and induction of apoptosis. Further preclinical and clinical investigations are necessary to elucidate the role of bisphosphonates, and large randomized clinical trials should be conducted to confirm the clinical value of bisphosphonates for the prevention of relapse, as well as for the maintainance of net bone density, e.g. during aromatase inhibitor therapy.
Collapse
Affiliation(s)
- D Lüftner
- Medizinische Klinik und Poliklinik II, Schwerpunkt Onkologie und Hämatologie, Universitätsmedizin Berlin, Charité, Campus Mitte, Humboldt-Universität zu Berlin, 10117 Berlin, Germany.
| | | | | |
Collapse
|
39
|
Pollmann D, Siepmann S, Geppert R, Wernecke KD, Possinger K, Lüftner D. The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancer. Anticancer Res 2007; 27:1853-62. [PMID: 17649784] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/16/2023]
Abstract
BACKGROUND The efficacy control for the treatment of bone metastases in breast cancer is difficult and usually initiated later and with longer time between treatment cycles than the restaging of visceral or soft tissue metastases. The amino-terminal propeptide (PINP) of type I collagen as a biochemical indicator of bone turnover might facilitate early and valid disease surveillance. The utility of total PINP was investigated in metastatic breast cancer patients, with or without bone metastases (for monitoring of therapy). The results were compared to the established markers, osteocalcin and beta-carboxyterminal telopeptide (CTX) or crosslaps concentration. PATIENTS AND METHODS Baseline serum samples of 51 patients with metastastic breast cancer under chemotherapy were investigated. In total, 38 patients had been diagnosed with bone metastases while 13 had no evidence of metastastic spread to the bone. All the patients with bone spread received bisphosphonates in addition to systemic chemotherapy and/or antibody therapy or hormonal treatment. Osteocalcin, CTX and PINP levels were measured on an Elecsys 2010 analyzer (electrochemiluminescence immunoassay--ECLIA). The normal cut-off values were: osteocalcin < 41.3 pg/ml, CTX < 1008 pg/ml and PINP < 95 ng/ml. Based on overall treatment outcome, the patients were grouped as responders (CR/PR), with stable disease (SD) or displaying primary progression (PD). RESULTS The baseline levels of PINP were significantly higher in patients with bone metastases (median: 92.8 ng/ml) than in those without (median: 63.2 ng/ml, p = 0.044). Patients with more than seven bone metastases had significantly higher PINP levels (median: 149.7 ng/ml) than those with fewer than seven (median: 67.6 ng/ml, p = 0.04). Significant differences were also found for osteocalcin and CTX, at p = 0.02 and p = 0.04, respectively, although the median levels remained under the normal cut-off levels. In terms of response assessment of bone spread, the PINP concentrations decreased in responders from 194.3 ng/ml to 100.4 ng/ml (p = 0.23). In patients with SD, PINP remained at the same level of approximately 70 ng/ml (p = 0.16), but increased in patients with PD from 83.4 ng/ml to 176.5 ng/ml (p = 0.14). These trends rather than statistical difference were probably due to the limited patient cohort. No differences were found for the serum concentrations of PINP, CTX and osteocalcin between post- and pre-menopausal women. CONCLUSION The PINP levels of the osseous metastatic breast cancer patients were elevated at baseline in comparison to those without bone involvement; the levels correlated to the number of bone metastases but were independent of the menopausal status. Thus, the levels of PINP under therapy might correlate with the response to therapy. Osteocalcin and CTX did not show similar sensitivity for the surveillance of bone metastases.
Collapse
Affiliation(s)
- D Pollmann
- Medizinische Klinik und Poliklinik II, Schwerpunkt Onkologie und Hämatologie, Universitätsmedizin Berlin, Charité, Campus Mitte, Humboldt-Universität zu Berlin, 10117 Berlin, Germany
| | | | | | | | | | | |
Collapse
|
40
|
Schmid P, Regierer A, Kiewe P, Schippinger W, Greil R, Lehenbauer-Dehm S, Niederle N, Freier W, Van de Velde H, Possinger K, Kuehnhardt D. Bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines: Final results of a phase I/II study. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.1072] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1072 Background: Capecitabine has shown substantial activity in taxane and/or anthracycline pretreated breast cancer patients. Bortezomib, a 26S proteasome inhibitor, has been shown to increase sensitivity to chemotherapy. This phase I/II trial was initiated to evaluate the combination of capecitabine and bortezomib in heavily pretreated patients with metastatic breast cancer. Methods: Patients with metastatic breast cancer and prior taxane and/or anthracycline therapy were treated with bortezomib (1.0–1.3 mg/m2; days 1, 4, 8 & 11) and capecitabine (1,500–2,500 mg/m2, days 1–14) in 3-weeks intervals for up to 8 cycles. Primary endpoints were to determine the optimal doses for the combination (phase I) and the tumor response rate (RR) (phase II). Secondary endpoints included safety, time to progression (TTP), duration of response (DR), and overall survival (OS). Results: A total of 35 patients were enrolled and 29 patients were assessable for response. The majority of patients had received 2 or 3 lines of chemotherapy (69% and 14%, respectively) prior to the study. The maximum tolerated doses (MTD) were bortezomib 1.3 mg/m2 and capecitabine 2500 mg/m2. Dose limiting toxicities were Grade 3 stomatitis in 1 out of 6 patients at 1.0/2,000 and Grade 3 diarrhea in 1 out of 6 patients at 1.3/2,500. Myelosuppression was low. Non-hematological toxicities were generally mild to moderate with no G4 toxicity being observed. Most common side effects were thrombocytopenia (Grade 3/4 27% of patients), diarrhea (18%), hand-foot syndrome (12%), peripheral neuropathy (12%), leucopenia (9%) and asthenia (9%). The overall RR was 17.2% and an additional 31% of patients had stable disease (31%; 4 unconfirmed). In the 21 patients treated at the MTD, RR was 17.6% and 47% of patients had SD. Median TTP and OS were 3.5 months (95% CI 1.9–4.4) and 7.5 months (95% CI 5.6–14.6), respectively. Median DR was 4.4 months. Conclusions: The combination of bortezomib and capecitabine is well tolerated and has moderate antitumour activity in heavily pretreated breast cancer. [Table: see text]
Collapse
Affiliation(s)
- P. Schmid
- Charing Cross Hospital, London, United Kingdom; Charite Campus Mitte, Berlin, Germany; Charite Campus Benjamin Franklin, Berlin, Germany; Universitaetsklinikum, Graz, Austria; Landeskliniken Salzburg, Salzburg, Austria; Klinikum Leverkusen, Leverkusen, Germany; Practice for Oncology and Hematology, Hildesheim, Germany; Johnson & Johnson Pharmaceutical Research & Develo, Beerse, Belgium
| | - A. Regierer
- Charing Cross Hospital, London, United Kingdom; Charite Campus Mitte, Berlin, Germany; Charite Campus Benjamin Franklin, Berlin, Germany; Universitaetsklinikum, Graz, Austria; Landeskliniken Salzburg, Salzburg, Austria; Klinikum Leverkusen, Leverkusen, Germany; Practice for Oncology and Hematology, Hildesheim, Germany; Johnson & Johnson Pharmaceutical Research & Develo, Beerse, Belgium
| | - P. Kiewe
- Charing Cross Hospital, London, United Kingdom; Charite Campus Mitte, Berlin, Germany; Charite Campus Benjamin Franklin, Berlin, Germany; Universitaetsklinikum, Graz, Austria; Landeskliniken Salzburg, Salzburg, Austria; Klinikum Leverkusen, Leverkusen, Germany; Practice for Oncology and Hematology, Hildesheim, Germany; Johnson & Johnson Pharmaceutical Research & Develo, Beerse, Belgium
| | - W. Schippinger
- Charing Cross Hospital, London, United Kingdom; Charite Campus Mitte, Berlin, Germany; Charite Campus Benjamin Franklin, Berlin, Germany; Universitaetsklinikum, Graz, Austria; Landeskliniken Salzburg, Salzburg, Austria; Klinikum Leverkusen, Leverkusen, Germany; Practice for Oncology and Hematology, Hildesheim, Germany; Johnson & Johnson Pharmaceutical Research & Develo, Beerse, Belgium
| | - R. Greil
- Charing Cross Hospital, London, United Kingdom; Charite Campus Mitte, Berlin, Germany; Charite Campus Benjamin Franklin, Berlin, Germany; Universitaetsklinikum, Graz, Austria; Landeskliniken Salzburg, Salzburg, Austria; Klinikum Leverkusen, Leverkusen, Germany; Practice for Oncology and Hematology, Hildesheim, Germany; Johnson & Johnson Pharmaceutical Research & Develo, Beerse, Belgium
| | - S. Lehenbauer-Dehm
- Charing Cross Hospital, London, United Kingdom; Charite Campus Mitte, Berlin, Germany; Charite Campus Benjamin Franklin, Berlin, Germany; Universitaetsklinikum, Graz, Austria; Landeskliniken Salzburg, Salzburg, Austria; Klinikum Leverkusen, Leverkusen, Germany; Practice for Oncology and Hematology, Hildesheim, Germany; Johnson & Johnson Pharmaceutical Research & Develo, Beerse, Belgium
| | - N. Niederle
- Charing Cross Hospital, London, United Kingdom; Charite Campus Mitte, Berlin, Germany; Charite Campus Benjamin Franklin, Berlin, Germany; Universitaetsklinikum, Graz, Austria; Landeskliniken Salzburg, Salzburg, Austria; Klinikum Leverkusen, Leverkusen, Germany; Practice for Oncology and Hematology, Hildesheim, Germany; Johnson & Johnson Pharmaceutical Research & Develo, Beerse, Belgium
| | - W. Freier
- Charing Cross Hospital, London, United Kingdom; Charite Campus Mitte, Berlin, Germany; Charite Campus Benjamin Franklin, Berlin, Germany; Universitaetsklinikum, Graz, Austria; Landeskliniken Salzburg, Salzburg, Austria; Klinikum Leverkusen, Leverkusen, Germany; Practice for Oncology and Hematology, Hildesheim, Germany; Johnson & Johnson Pharmaceutical Research & Develo, Beerse, Belgium
| | - H. Van de Velde
- Charing Cross Hospital, London, United Kingdom; Charite Campus Mitte, Berlin, Germany; Charite Campus Benjamin Franklin, Berlin, Germany; Universitaetsklinikum, Graz, Austria; Landeskliniken Salzburg, Salzburg, Austria; Klinikum Leverkusen, Leverkusen, Germany; Practice for Oncology and Hematology, Hildesheim, Germany; Johnson & Johnson Pharmaceutical Research & Develo, Beerse, Belgium
| | - K. Possinger
- Charing Cross Hospital, London, United Kingdom; Charite Campus Mitte, Berlin, Germany; Charite Campus Benjamin Franklin, Berlin, Germany; Universitaetsklinikum, Graz, Austria; Landeskliniken Salzburg, Salzburg, Austria; Klinikum Leverkusen, Leverkusen, Germany; Practice for Oncology and Hematology, Hildesheim, Germany; Johnson & Johnson Pharmaceutical Research & Develo, Beerse, Belgium
| | - D. Kuehnhardt
- Charing Cross Hospital, London, United Kingdom; Charite Campus Mitte, Berlin, Germany; Charite Campus Benjamin Franklin, Berlin, Germany; Universitaetsklinikum, Graz, Austria; Landeskliniken Salzburg, Salzburg, Austria; Klinikum Leverkusen, Leverkusen, Germany; Practice for Oncology and Hematology, Hildesheim, Germany; Johnson & Johnson Pharmaceutical Research & Develo, Beerse, Belgium
| |
Collapse
|
41
|
Luftner D, Pechlivanis K, Geppert R, Stroux A, Possinger K. Analysis of the prognostic value of the shed antigen of HER2/neu in premenopausal breast cancer patiens in the TABLE study. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.11007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
11007 Background: The HER-2/neu oncoprotein is a transmembrane tyrosine kinase that belongs to the family of epidermal growth factor receptors. It is known to be overexpressed in 20–40% of breast cancers. Increased serum HER-2/neu (sHER-2/neu) concentrations at the beginning of adjuvant breast cancer therapy have been shown to be of prognostic importance (Mehta et al, 1998). Using the sera from the Takeda® Adjuvant Breast Cancer Study with Leuprorelin (TABLE study), we tested for the prognostic value of sHER-2/neu. Methods: A total of 133 premenopausal, node-positive, hormone-receptor positive patients received either 11.25 mg of leuprorelin s.c. every 3 months over 2 years or CMF chemotherapy for 6 cycles. Blood samples were collected at baseline and at 3, 6, 12, 18, 24 and 30 mo. The primary endpoint of the study was to determine the relapse-free survival (RFS) after 2 years. sHER-2/neu was measured using a standardized ELISA (upper limit of normal 15 ng/ml). As the baseline sHER-2/neu concentrations ranged from 3.8–14.0 ng/ml, results were grouped in terciles. Data were analyzed using Kaplan-Meier and Cox Proportional Hazards survival analysis. Results: Material was available from 80 patients in leuprorelin arm and 53 patients in CMF arm. 65 of 133 patients had relapsed during the follow-up time of up 7 years after treatment. The median RFS was 62.9 mo. The RFS time depended on the concentrations of sHER-2/neu at baseline: RFS was significantly shorter in patients of the third tercile with sHER-2/neu levels >8.8 ng/ml than in patients of the first tercile with levels <7.2 ng/ml (p=0.0232). Five years after initial therapy, we found that 73% of patients in the first tercile group of baseline sHER-2/neu had no relapse. In the second tercile, 63.3% of patients were relapse-free, while in the third tercile only 47.2% of patients had not suffered from a relapse. Conclusions: Higher sHER-2/neu concentrations at the beginning of adjuvant therapy in the TABLE-Study have a prognostic importance for RFS. This observation was evaluated irrespective of the HER-2/neu tissue status and could be of clinically importance for adjuvant therapy with the monoclonal anti-HER-2/neu antibody trastuzumab or other anti-HER-2/neu targeted therapies. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- D. Luftner
- Charite, Berlin, Germany; Institut für Biometrie und Klinische Epidemiologie, Berlin, Germany
| | - K. Pechlivanis
- Charite, Berlin, Germany; Institut für Biometrie und Klinische Epidemiologie, Berlin, Germany
| | - R. Geppert
- Charite, Berlin, Germany; Institut für Biometrie und Klinische Epidemiologie, Berlin, Germany
| | - A. Stroux
- Charite, Berlin, Germany; Institut für Biometrie und Klinische Epidemiologie, Berlin, Germany
| | - K. Possinger
- Charite, Berlin, Germany; Institut für Biometrie und Klinische Epidemiologie, Berlin, Germany
| |
Collapse
|
42
|
Jehn CF, Siebmann S, Pecher G, Wernicke K, Possinger K, Lüftner D. First safety and response results of a randomized phase III study with liposomal platin in the treatment of advanced squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.6040] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
6040 Background: Cisplatin is one of the most active chemotherapeutic agents used in the treatment of advanced squamous cell carcinoma of the head and neck (SCCHN). However, its clinical efficacy is limited by its renal- and hematotoxicity profile. In a randomized, multicenter phase III trial, we replaced conventional cisplatin by a liposomal formulation of cisplatin (lipoplatin), and compared the safety and efficacy profiles of patients (pts) in the two treatment arms. Methods: Arm A: 100 mg/m2/d lipoplatin (d 1,8,15) plus 1,000 mg/m2/d 5-FU (d 1–5) q3w for 6 cycles; arm B: 100 mg/m2/d cisplatin (d 1) plus 1,000 mg/m2/d 5-FU (day 1–5) q3w for 6 cycles. Inclusion criteria: histologically confirmed SCCHN, age 18–75, renal function (creatinine clearance >50 ml/min) and primary metastatic disease or progressive SCCHN. Results: 62 pts were randomized, from which 43 pts (39 m; 4 w) were evaluable for outcome and toxicity. In the cisplatin arm hematotoxicity was more frequent (grades I/II: 28 pts, grades III/IV: 2 pts) than in the lipoplatin arm (grades I/II: 15 pts, grades III/IV: 3 pts). The rate of anemia was similar between the treatment arms. 13 pts in the lipoplatin arm experienced renal toxicity with (grade I: 3pts) and (grade II: 10 pts), as measured by a reduction of the creatinine clearance (grade I: 99–75 ml/min; grade II: 74–50 ml/min; grade III: <50 ml/min). Renal toxicity occurred in 8 patients in the cisplatin arm with 1 pt (grade I) and 3 pts (grade II), however 5 pts developed grade III. No renal toxicity grade III was developed in the lipoplatin arm until now. Outcome was as follows: lipoplatin arm: PR: 3 pts; SD: 13 pts; PD: 9 pts; cisplatin arm: PR: 8 pts; SD: 9 pts; PD: 1 pts. Thus, the non-PD pts (PR or SD) was 16/25 (64 %) in the lipoplatin arm vs 17/18 (94%) cases in the cisplatin arm. Conclusions: Liposomal platin seems to reduce both the renal and hematological toxicity as compared to conventional cisplatin to a clinically relevant extent. This reduction of side effects will influence the chance to preserve the dose density of chemotherapy, and thereby, the efficacy of treatment. No significant financial relationships to disclose.
Collapse
Affiliation(s)
| | | | - G. Pecher
- Charite Campus Mitte, Berlin, Germany
| | | | | | | |
Collapse
|
43
|
Emde AM, Maslak K, Liu H, Reles AE, Possinger K, Eucker J. Combination of fulvestrant and lapatinib in non-HER2-overexpressing and adriamycin-resistant breast cancer cell lines. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.14050] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
14050 Background: We evaluated whether combination of lapatinib, a dual tyrosine kinase inhibitor against EGFR and HER2, and fulvestrant, a full estrogen receptor antagonist, is superior in EGFR and HER2 overexpressing and non-overexpressing breast cancer cell lines regarding cell growth inhibition and effects on the protein expression level on special proteins such as PDK1 and ERK1/2. Methods: MTT assay and western blot analysis were performed in the different breast cancer cell lines BT474, T47D, MCF-7 and Adriamycin resistant MCF7 cells. Incubation time was 72h. Concentration of both agents in western blot: 1x10exp-7M, in MTT assay 10exp-11M to 10exp-5M. Results: MTT assay showed a significant stronger proliferation inhibition by lapatinib and fulvestrant in BT474 cells and non- overexpressing T47D cells at a concentration of 10E-7M compared to single agent treatment. By western blot analysis, we found a synergistic downregulation of PDK1 in the combination treatment both in BT474 and AR MCF7 cells, whereas not in T47D cells. In MCF7 cells a downregulation of p-PDK1 was observed after treatment with fulvestrant alone as well as lapatinib plus fulvestrant. Regarding ERK1/2, a synergistic downregulation could be observed in AR MCF7 cells. A downregulation of a p-ERK was detected in MCF-7 cells after treatment with lapatinib, fulvestrant or both. Conclusion: A synergistic action of lapatinib and fulvestrant was observed in all 4 cell lines despite their different receptor status regarding EGFR, HER2 and ER alpha. Shadeo et al. (2005) showed different copy number profiles in these breast cancer cell lines regarding the examined pathways. We could show by western blot analysis that the combination treatment had inhibitory effect on these cell lines according to their individual up-regulated pathways. Altogether, this suggests that the combination is a promising treatment not only in EGFR and HER2 over-expressing breast cancer and that treatment effect is also dependent on up-regulated pathways more likely than receptor status. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- A. M. Emde
- University Hospital Charite, Berlin, Germany
| | - K. Maslak
- University Hospital Charite, Berlin, Germany
| | - H. Liu
- University Hospital Charite, Berlin, Germany
| | - A. E. Reles
- University Hospital Charite, Berlin, Germany
| | | | - J. Eucker
- University Hospital Charite, Berlin, Germany
| |
Collapse
|
44
|
Abstract
Primary goals of treatment in metastatic breast cancer include prevention and palliation of symptoms, maintenance or improvement of quality of life and prolongation of survival. In order to account for the variability of clinical courses, treatment decisions have to be made on an individual basis. Low risk patients without evidence of rapid disease progression or symptomatic disease are mainly considered for endocrine treatment or single agent chemotherapy, whereas patients at higher risk with rapidly progressive or symptomatic disease are candidates for poly-chemotherapies. Anthracyclines are one of the most active group of agents and remain active after adjuvant pre-treatment. The use of liposomal derivatives or weekly or prolonged application can decrease the risk of cardiotoxicity. There is only incomplete cross-resistance between anthracyclines and taxanes. Taxane-based weekly or 3 weekly regimens are therefore generally used in anthracycline-pretreated patients. Capecitabine, gemcitabine, or vinorelbine constitute candidate agents after failure of anthracyclines and/or taxanes and may result in objective responses or disease stabilisation. Data on the continuation beyond third-line chemotherapy are insufficient. Decisions have therefore to be made on an individual basis.
Collapse
Affiliation(s)
- P Schmid
- Charing Cross and Hammersmith Hospital, Imperial College London, United Kingdom.
| | | |
Collapse
|
45
|
Jehn CF, Boulikas T, Kourvetaris A, Possinger K, Lüftner D. Pharmacokinetics of liposomal cisplatin (lipoplatin) in combination with 5-FU in patients with advanced head and neck cancer: first results of a phase III study. Anticancer Res 2007; 27:471-5. [PMID: 17352269] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/14/2023]
Abstract
BACKGROUND Lipoplatin, a novel liposomal formulation of cisplatin, is composed of cisplatin and liposomes based on dipalmityl phosphatidyl glycerol (DPPG), soy phosphatidyl choline (SPC-3), cholesterol and methoxypolyethylene glycol-distearoyl phosphatidylethanolamine (mPEG2000-DSPE). Liposomal encapsulation of cisplatin is designed to increase safety and tolerability by decreasing, e.g., nephrotoxicity through decreased exposure of organs to cisplatin, while effectively delivering the drug to the tumor. In an ongoing phase III trial comparing cisplatin to lipoplatin (both in combination with infusional high-dose 5-Fluoruracil) in advanced head and neck cancer (HNC), a sub-study to determine the pharmacokinetic profile of lipoplatin in comparison to conventional cisplatin was undertaken. MATERIALS AND METHODS In total, twelve patients with advanced HNC received a combination chemotherapy with either lipoplatin/5-FU or cisplatin/5-FU. Plasma samples were analyzed for concentration of total platinum in patients from both arms. RESULTS All twelve patients from the pharmacokinetic sub-study were male Caucasians at a mean age of 60 years. There was no difference in age or kidney function between the two treatment groups. The total body clearance for cisplatin was 1.25 L/(hxm2) for the liposomal formulation, compared to 0.62 L/(hxm2) for conventional cisplatin. The terminal half life was half as long for lipoplatin (10.98 h) as compared to cisplatin (24.5h). Even though the maximum observed concentration in the plasma (C(max) was greater for lipoplatin than for cisplatin, the area under the concentration time-curve (AUC) was less (6.5 microg/ml vs. 4.07 microg/ml and 66.85 microg/h/ml vs. 130.33 microg/h/ml, respectively). CONCLUSION The pharmacokinetic profile of lipoplatin (in combination with 5-FU) suggests that the liposomal formulation results in a greater body clearance and shorter half life than conventional cisplatin, which confirms the clinical observation of decreased taxicity, especially renal deterioration.
Collapse
Affiliation(s)
- C F Jehn
- Medizinische Klinik und Poliklinik mit Schwerpunkt Onkologie und Hämatologie Charité, Campus Mitte, Universitätsmedizin Berlin, Humboldt-Universität zu Berlin Charitéplatz 1, 10117 Berlin, Germany
| | | | | | | | | |
Collapse
|
46
|
Eucker J, Emde A, Possinger K. [Treatment of breast cancer: from hormones to antibodies]. Internist (Berl) 2006; 47:1223-4, 1226-8. [PMID: 17063333 DOI: 10.1007/s00108-006-1728-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
Breast cancer, as one of the most frequent tumor entities, is the object of intensive research activity. Clinical research over the last few years has resulted in an increasing differentiation in treatment strategies in the adjuvant setting as well as in metastatic breast cancer. Treatment decision is guided by different risk groups, and relevant changes in clinical practice have arisen in hormonal treatment as well as in chemotherapy. Furthermore, new agents have shown clinical activity, in particular trastuzumab has emerged as standard treatment in HER2 positive breast cancer. It was even licensed in 2006 for adjuvant treatment.
Collapse
Affiliation(s)
- J Eucker
- Medizinische Klinik mit Schwerpunkt Onkologie und Hämatologie, Charité, Universitätsmedizin Berlin, Berlin.
| | | | | |
Collapse
|
47
|
Beslija S, Bonneterre J, Burstein H, Cocquyt V, Gnant M, Goodwin P, Heinemann V, Jassem J, Köstler WJ, Krainer M, Menard S, Petit T, Petruzelka L, Possinger K, Schmid P, Stadtmauer E, Stockler M, Van Belle S, Vogel C, Wilcken N, Wiltschke C, Zielinski CC, Zwierzina H. Second consensus on medical treatment of metastatic breast cancer. Ann Oncol 2006; 18:215-25. [PMID: 16831851 DOI: 10.1093/annonc/mdl155] [Citation(s) in RCA: 83] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Abstract
The present consensus manuscript defines evidence-based recommendations for state-of-the-art treatment of metastatic breast cancer depending on disease-associated and biologic variables.
Collapse
Affiliation(s)
- S Beslija
- Central European Cooperative Oncology Group (CECOG), Schwarzspanierstrasse 7/5, A-1090 Vienna, Austria
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Siepmann S, Pollmann D, Geppert R, Wernecke KD, Possinger K, Lueftner D. Tissue inhibitor of metalloproteinases 1 (TIMP-1) and tumor type M2 pyruvate kinase (TuM2-PK) were compared with established markers in advanced colorectal cancer. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.13537] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
13537 Background: Recently, a high expression of TIMP-1 was demonstrated by immunohistochemistry in colorectal cancer (CRC). TIMP-1 can also be detected in plasma of those patients (pts). We investigated the longitudinal concentrations of TIMP-1 in 37 pts with advanced CRC and correlated the monitoring performance of TIMP-1 to CEA and CA 19–9 as established markers of tumor load in CRC. In addition, the plasma level of TuM2-PK as novel marker of disease activity was integrated into the analysis. Methods: Plasma TIMP-1 (Bayer Diagnostics/Oncogene Science, Tarrytown/Boston, USA) and TuM2-PK (Schebo Biotech, Giessen, Germany) levels were measured using standardized ELISA assays while serum CEA and CA 19–9 were determined using chemiluminescence immunoassays (Bayer Diagnostics, Tarrytown/NY). The nonparametric analysis of variance for repeated measurements by Brunner was used to test for time effects between the selected 3 time points: 1. baseline at initiation of systemic chemotherapy for metastatic disease; 2: best response; 3: later progression. Results: We grouped 37 pts with regard to best response to chemotherapy as follows: complete or partial remission (CR/PR): n=10; stable disease (SD): n=21; primary progressive disease (PD): n=6. TIMP-1 and TuM2-PK concentrations increased significantly from baseline to progression (p<0.001 and p=0.003, respectively). The plasma levels of patients with objective response (CR/PR) dropped significantly for TuM2-PK (p=0.001) and TIMP-1 (p=0.001), while CA 19–9 and CEA did not change (p=0.94 and p=0.10, respectively). No significant change could be demonstrated in the SD group for TuM2-PK (p=0.26), TIMP-1 (p=0.69) and for CEA (p=0.25), whereas CA 19–9 concentrations decreased significantly (p=0.04). Conclusions: Innovative markers like TIMP-1 and TuM2-PK provided a much higher monitoring quality than established markers like CEA and CA 19–9 in advanced CRC. As the later cancer-associated proteins are recommended by internationally acknowledged guidelines, larger comparative trials are warranted asking the important question whether a replacement of CEA by one or a panel of new markers may provide additional clinical information. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- S. Siepmann
- Universitaetsklinikum Charite, Berlin, Germany; Institut für Medizinische Biometrie, Berlin, Germany
| | - D. Pollmann
- Universitaetsklinikum Charite, Berlin, Germany; Institut für Medizinische Biometrie, Berlin, Germany
| | - R. Geppert
- Universitaetsklinikum Charite, Berlin, Germany; Institut für Medizinische Biometrie, Berlin, Germany
| | - K. D. Wernecke
- Universitaetsklinikum Charite, Berlin, Germany; Institut für Medizinische Biometrie, Berlin, Germany
| | - K. Possinger
- Universitaetsklinikum Charite, Berlin, Germany; Institut für Medizinische Biometrie, Berlin, Germany
| | - D. Lueftner
- Universitaetsklinikum Charite, Berlin, Germany; Institut für Medizinische Biometrie, Berlin, Germany
| |
Collapse
|
49
|
Luftner D, Siepmann S, Christian J, Pollmann D, Pecher G, Wernecke KD, Possinger K. Randomized, phase III trial comparing liposomal platin with cisplatin in patients (pts) with advanced squamous cell carcinoma of the head & neck (SCCHN) regarding safety and efficacy profiles. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.5564] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5564 Background: Based on a metanalysis of > 16,000 patients (Bourhis, ASCO 2004), cisplatin emerges as the essential agent for the treatment of advanced SCCHN. However, its clinical use is impeded by its severe adverse reactions, as renal toxicity. In a randomized, phase III trial we replaced conventional cisplatin by a liposomal formulation of cisplatin (lipoplatin) and compared the safety and efficacy profiles. Methods: The study was designed for two treatment arms: A: 100 mg/m2/d lipoplatin (d 1,8,15) plus 1,000 mg/m2/d 5-FU (d 1–5) q3w for 6 cycles; B: 100 mg/m2/d cisplatin (d 1) plus 1000 mg/m2/d 5-FU (d 1–5) q3w for 6 cycles. Main inclusion criteria selected pts with primary metastatic, relapsed or progressive SCCHN between 18–75 years and creatinin clearance >50ml/min. Main endpoints for this interims analysis were hemato- and nephrotoxicity. First response data were collected. The study was designed for non-inferiority. Results: Out of 41 randomized pts, 30 pts are evaluable for toxicity (15 pts for every arm) and 27 pts (15 pts for lipoplatin, 12 pts for cisplatin) for outcome. In the cisplatin arm hematotoxicity was more frequent (leucopenia grade I/II: 5 pts, grade III/IV: 3 and 1 pts vs 5 pts with grade I/II in the lipoplatin arm). The rate of anemia was similar between the treatment arms. A total of 11 pts in the lipoplatin arm experienced renal toxicity grade I/II as measured by a reduction of the creatinine clearance and 12 pts in the cisplatin arm (grade I/II: 7 pts; grade III: 5 pts). No renal toxicity grade III was developed in the lipoplatin arm until now. Outcome was as follows: lipoplatin arm: PR: 1 pt; SD: 6 pts; PD: 8 pts; cisplatin arm: PR: 7 pts; SD: 3 pts; PD: 2 pts. Thus, the non-PD pts (PR or SD) is 7/15 (47%) in the lipoplatin arm vs 10/12 (83%) cases in the cisplatin arm. Conclusions: Liposomal platin seems to reduce both the hematological and non-hematological toxicity profiles as compared to conventional cisplatin to a clinically relevant extent. As patients with advanced SCCHN have an increased risk of renal toxicity due to poor hydration, the observed reduction of side effects will influence the chance to preserve the dose density of chemotherapy, and thereby, the efficacy of treatment. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- D. Luftner
- Medizinische Klinik II, Berlin, Germany; Institut für Medizinische Biometrie, Berlin, Germany
| | - S. Siepmann
- Medizinische Klinik II, Berlin, Germany; Institut für Medizinische Biometrie, Berlin, Germany
| | - J. Christian
- Medizinische Klinik II, Berlin, Germany; Institut für Medizinische Biometrie, Berlin, Germany
| | - D. Pollmann
- Medizinische Klinik II, Berlin, Germany; Institut für Medizinische Biometrie, Berlin, Germany
| | - G. Pecher
- Medizinische Klinik II, Berlin, Germany; Institut für Medizinische Biometrie, Berlin, Germany
| | - K. D. Wernecke
- Medizinische Klinik II, Berlin, Germany; Institut für Medizinische Biometrie, Berlin, Germany
| | - K. Possinger
- Medizinische Klinik II, Berlin, Germany; Institut für Medizinische Biometrie, Berlin, Germany
| |
Collapse
|
50
|
Jehn CF, Becker B, Pfeiffer S, Krebs M, Possinger K, Flath B, Dieing A. Cognitive dysfunction, brain-derived neurotrophic factor and IL-6 levels in cancer patients with depression. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.8632] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
8632 Background: Increased proinflammatory cytokines (IL-6) and decreased brain-derived neurotrophic factor (BDNF) levels have been implicated in the pathophysiology of depression. Depression has been shown to be associated with cognitive dysfunction. The objective of this study was to assess the correlations between cognitive dysfunction, IL-6 and BDNF in cancer patients (pts) with depression. Methods: Depression was assessed in 55 patients with metastatic cancer by the Hospital Anxiety and Depression Scale (HADS) and diagnosis was established according to DSM-IV criteria. Cognitive function was assessed by the Auditory Verbal Learning Test (AVLT). Plasma concentrations of Interleukin-6 and BDNF were measured at 8 AM the same day. In the statistical analysis the Mann-Whitney test and the Pearson correlation were applied. Results: Pts characteristics (n=55): median age 60 y (25–85); 76.9% Females, 23.1% males. 52% of pts had depression. There were no significant differences in mean age or Karnofsky-index between pts with and without depression. Depression was associated with a significant higher median IL-6 level (14.8 vs. 3.7 pg/ml; p<0,001). For Cognitive function only the longterm memory was significantly reduced in depression (p=0.01). However, there was no difference in BDNF levels between both groups (p=0.164). There were correlations between HADS-D score and IL6 (r=4.11; p=0.002), IL-6 and BDNF (r= −0.42; p=0.001), BDNF and longterm memory (r=0.48; p=0.02). No correlations were found for level of depression (HADS-D score) and BDNF levels (r= −0.20; P=0.14). Conclusions: Depression and increased plasma IL-6 concentrations are strongly associated in pts with cancer. There seems to be no association between BDNF and depression in cancer pts. However there is a positive correlation between the cognitive function, at least for longterm memory, with BDNF. No significant financial relationships to disclose.
Collapse
Affiliation(s)
| | - B. Becker
- Charité Campus Mitte, Berlin, Germany
| | | | - M. Krebs
- Charité Campus Mitte, Berlin, Germany
| | | | - B. Flath
- Charité Campus Mitte, Berlin, Germany
| | - A. Dieing
- Charité Campus Mitte, Berlin, Germany
| |
Collapse
|